Sinonasal Cancer Study to Evaluate Oncologic Outcomes and Quality of Life
Summary
This is a multi-institution prospective study of patients with sinonasal malignancies. The goal of this study is to learn more about the course of sinonasal cancer, treatment outcomes, and patient quality of life. In addition, central mutational and genomic analysis of tumor tissue will be evaluated.
Outcome measures
Primary
Oncologic outcomes as measured by overall survival, disease specific survival and recurrence free survival
Time frame: Through study completion, an average of 5 years
Secondary
Quality of life outcomes including the University of Washington Quality of Life Questionnaire (UW-QOL v4) and the Sinonasal Outcome Test 22 (SNOT22)
Time frame: Through study completion, an average of 5 years
Describe the molecular foundation of sinonasal malignancies utilizing RNA sequencing to identify transcriptomic tumor profiles
Time frame: Through study completion, an average of 5 years
Eligibility criteria
Study locations (1)
Mayo Clinic in Rochester
Rochester, Minnesota, 55905